Disclosure: Garen Manvelian, MD, is a consultant for Iroko Pharmaceuticals, LLC. Allan Gibofsky, MD, has participated in a scientific advisory board for Iroko Pharmaceuticals, LLC. Stephen Daniels, DO, is an employee of Premier Research Group International, LLC, which was contracted to complete this Phase 2 clinical trial.
Original Research Article
A Phase 2 Study Evaluating the Efficacy and Safety of a Novel, Proprietary, Nano-Formulated, Lower Dose Oral Diclofenac
Version of Record online: 8 OCT 2012
Wiley Periodicals, Inc.
Volume 13, Issue 11, pages 1491–1498, November 2012
How to Cite
Manvelian, G., Daniels, S. and Gibofsky, A. (2012), A Phase 2 Study Evaluating the Efficacy and Safety of a Novel, Proprietary, Nano-Formulated, Lower Dose Oral Diclofenac. Pain Medicine, 13: 1491–1498. doi: 10.1111/j.1526-4637.2012.01479.x
- Issue online: 14 NOV 2012
- Version of Record online: 8 OCT 2012
Vol. 14, Issue 10, 1615, Version of Record online: 16 OCT 2013
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.